Introduction
The Abl family of proteins encodes non-receptor tyrosine kinases that include Abl and the Abl related protein; Arg (Kruh et al., 1986; Wang et al., 1984) . Abl proteins have also been identi®ed in other species, suggesting that they represent an evolutionary conserved family of signaling molecules. Mutations leading to gain of function in Abl have been associated with transformation (Rosenberg and Witte, 1988) . Abl oncoproteins include the retroviraly-transduced product of Abl, v-Abl, and the product of two chromosomal translocations found in human leukemias; BCR-Abl and TEL-Abl (Golub et al., 1996b; McWhirter and Wang, 1997) (Figure 1 ). Compared to c-Abl, proteins encoded by abl oncogenes are constitutively active and mostly cytosolic. Whereas v-Abl is predominantly associated with the inner lea¯et of the plasma membrane (Van Etten et al., 1989a) , BCR-Abl and TEL-ABL proteins are predominantly found associated with cytoskeletal actin ®laments (Golub et al., 1996a; McWhirther and Wang, 1991; Papadopoulos et al., 1995) .
Characterization of signaling pathways activated by Abl tyrosine kinases has been a useful approach in understanding the function of both cellular and oncogenic forms of Abl (Laneuville, 1995) . These studies, in addition to genetic manipulation of abl genes (Schwartzberg et al., 1991; Tybulewicz et al., 1991) , have suggested that Abl proteins may be involved in multiple cellular processes. The majority of Abl-interacting proteins or substrates identi®ed to date are proteins involved in the transduction of signals leading to gene transcription and cellular proliferation or survival (reviewed in Zou and Calame, 1999) . Several of these signaling pathways are activated by both v-Abl and BCR-Abl, including Ras, Myc, and PI3-kinase. The above observations suggest that the transformation program initiated by Abl oncoproteins is likely to consist of multiple signals. An additional layer of complexity is based on the fact that the combination of signals required for Abl-mediated transformation may vary with cellular context.
In this review, we will describe observations from our laboratory that initially demonstrated constitutive activation of the JAK-STAT pathway downstream of the abl oncogenes. We will summarize our recent studies characterizing the molecular mechanism underlying v-Abl-induced activation of JAKs and STATs, and compare our observations with those reported for BCR-Abl-induced STAT activation. Finally, we discuss the biological signi®cance of cytokine signal transduction in transformation by abl oncogenes.
Abl proteins and B cell development
Initial characterization of Abelson murine leukemia virus (A-MuLV) suggested that, while in vitro this virus can transform many dierent cell types, in vivo, it generates tumors of pre-B cell origin (Rosenberg, 1994) . B cell precursors in bone marrow are normally dependent on cytokines produced by bone marrow stromal cells for proliferation and survival. Upon infection with A-MuLV, bone marrow cells arrest at the pro/pre-B stage of development. This stage of dierentiation is marked by high frequency of immunoglobulin heavy chain rearrangement (IgH), expression of l5 and VpreB surrogate light chain genes, and up-regulation of markers such as CD43, BP-1, HSA, and the interleukin 7 receptor (IL-7R) (Melchers et al., 1995) . In addition to dierentiation arrest, the transformation program by the abl oncogene is accompanied by the loss of cytokine dependent growth (Overell et al., 1991; Young et al., 1991) .
Studies in a pre-B cell line transformed with a temperature sensitive (ts) mutant of v-Abl have established that the arrest at the pre-B stage of dierentiation is clearly dependent on the tyrosine kinase activity of v-Abl. Upon shift to non-permissive temperatures and inactivation of v-Abl kinase activity, the B lymphocyte dierentiation program resumes; RAG-1 and RAG-2 genes are highly induced, NF-kB is activated, and germline RNAs corresponding to the light chain loci accumulate (Chen et al., 1994) . Concomitant with the above changes at nonpermissive temperatures, cells appear to arrest at the G1 phase of the cell cycle, and if not rescued by BCL-2 overexpression, they undergo apoptosis. The above studies also indicated that at non-permissive temperatures, the B cell dierentiation program resumes before a complete G1 arrest. Therefore, it appears that, at least in this experimental system, an active v-Abl kinase provides two distinct sets of signals; it blocks dierentiation and it promotes G1 transition.
Interestingly, the phenotype of the above-mentioned pre-B cell line at non-permissive temperatures resembles that of the pre-B cells in interleukin 7 (IL-7) or interleukin 7 receptor (IL-7R) de®cient mice (Corcoran et al., 1998; Peschon et al., 1994; von Freeden-Jery et al., 1995) . Targeted disruption of IL-7 or IL-7R genes in mice results in a severe defect in the B cell compartment, especially the subset undergoing IgH rearrangement (Corcoran et al., 1998) . Thus both vAbl or IL7-have the capacity to signal G1/S transition in this subset of B cells (Yasunaga et al., 1995) . In support for the role of IL-7 in mitogenesis and survival, various lines of IL-7 transgenic mice develop lymphoma of B cell origin (Fisher et al., 1993 (Fisher et al., , 1995 . Consistent with the phenotype of IL-7 transgenic mice, Overell et al. (1991) showed that a small percentage of pre-B cells infected with IL-7 encoding retroviruses became transformed and tumorigenic. The above observations suggest that A-MuLV and IL-7 may overlap in certain signaling pathways they activate in B lymphocyte progenitors.
Constitutive STAT activation downstream of v-Abl
In order to elucidate the mechanism of IL-7 independent growth of A-MuLV-transformed pre-B cells, we initially set out to analyse the JAK-STAT pathway in these cells. Initial experiments using a pre-B cell line transformed with the temperature sensitive mutant of v-Abl suggested that a link might exist between an active v-Abl kinase and cytokine signal transduction. In the presence of an active v-Abl kinase, constitutive GAS binding activities corresponding to STAT 5 and STAT 6 proteins were detected, and inactivation of vAbl tyrosine kinase resulted in abrogation of STAT activation (Danial et al., 1995) . Additional experiments established that STATs activated downstream of v-Abl can also be detected in freshly infected bone marrow cells, and is therefore not an artifact of long term tissue culture cell lines. Furthermore, v-Abl and STATs are functionally linked. Co-transfection of v-Abl expression construct with various STAT reporter genes results in cytokine independent transcriptional activation (NN Danial and PB Rothman, unpublished observations). Interestingly, we have not been able to detect constitutive STAT activation in IL-7-independent pre-B cell lines transformed with other oncogenes, including v-H-ras, fes, and v-Src. It is possible that, in Figure 1 Schematic diagram of Abl proteins. SH, Src homology domain; PTK, protein tyrosine kinase domain; NLS, nuclear localization signal; Myr, myristoyl moiety; BCR, break point cluster region; HLH, helix ± loop ± helix domain the context of pre-B cells, constitutive STAT activation might be a unique function of v-Abl, and that IL-7-independent growth of pre-B cells transformed by the above oncoproteins may be achieved by activation of other signaling pathways, in a manner independent of JAK-STAT. This is consistent with recent studies comparing the mechanism of IL-7-independent growth of pre-B cell infected with Abl/Myc or Raf/Myc retroviruses. Only Abl/Myc-infected pre-B cells exhibit constitutive activation of JAK-STAT signaling (Hilbert et al., 1998) .
The ability of v-Abl to activate STATs is not unique to its pre-B cell targets. Fibroblasts transformed by this oncoprotein also exhibit constitutive GAS binding activities (NN Danial and PB Rothman, unpublished observations) . However, the pattern of STAT activation by v-Abl seems to be cell context/cell lineage dependent. While STATs 5 and 6 are consistently activated in A-MuLV pre-B cells, in A-MuLV ®broblasts, activation of STATs 1 and 6 can be detected. While JAK 1 is consistently activated in all A-MuLV cells examined, JAK 2 is activated in AMuLV ®broblasts and a subset of pre-B cells, and JAK 3 is activated in pre-B cells (®broblasts do not express JAK 3). Although there is selectivity underlying v-Ablinduced JAK-STAT signaling in dierent cell types, it is not clear how this selectivity is achieved at the molecular level. It is possible that the availability or abundance of speci®c cytokine receptors in particular cell types may be important in determining the pattern of STAT activation by v-Abl. For example, consistent with the absence of IL-7R (which speci®cally recruits STAT 5) in ®broblasts, STAT 5 is not phosphorylated in A-MuLV 3T3 ®broblasts.
Mechanism of v-Abl-induced STAT activation
In A-MuLV-transformed pre-B cells, constitutive activation of STATs can be correlated with that of JAK kinases, mainly JAK 1 and JAK 3 (Danial et al., 1995) . Cytokine independent activation of JAKs in these cells also requires an active v-Abl kinase, and is not dependent on an autocrine loop. Analysis of v-Abl and JAK containing protein complexes established that v-Abl and JAKs associate in vivo, suggesting that JAK kinases may be v-Abl substrates. Additional biochemical analysis of JAK 1 : v-Abl association, both in vitro and in vivo, have de®ned a novel domain in the carboxy terminal region of v-Abl which is required for JAK 1 binding (Danial et al., 1998) . Our preliminary studies also suggest that the same region in the carboxyl terminus portion of v-Abl may interact with JAK 3. Deletion of this domain in v-Abl severely impairs the ability of this protein to activate STATs and JAK 1 (Danial et al., 1998) These experiments are consistent with our observations that inducible expression of a kinase inactive JAK 1 mutant down-regulates v-Abl-induced STAT activation (Danial et al., 1998) . Therefore, JAK 1 may be an intermediary kinase between v-Abl and STATs.
The amino acid composition of the JAK 1 binding domain of v-Abl shows interesting features. Several proline-rich sequences in this region fall loosely within the box1 consensus site de®ned for the binding of JAK kinases to cytokine receptors (Fukunaga et al., 1991; Miura et al., 1993) . It is possible that JAK-binding consensus sites may exist in other signaling proteins. Indeed a recent study reported that the latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV), which is important in EBV-mediated immortalization of B cells, binds JAK 3 through domains within its cytoplasmic region that resemble that of box1/2 motifs (Gires et al., 1999) . JAK 3 binding and activation by LMP1 is required for EBV-induced activation of STATs 1 and 3. These observations provide a molecular mechanism for previously reported constitutive JAK-STAT activation in EBV-transformed human B cells (Murata and Puri, 1997; . It is striking that box1/2-like motifs are conserved in cytokine receptors and some viral oncoproteins, and may enable transforming viruses to activate cytokine signaling pathways upon infection of their target cells. It is tempting to speculate that, in addition to LMP-1 and v-Abl, box1/2-like motifs may exist in other viral or cellular proteins, and may serve to recruit JAKs and mimic a constitutively active cytokine receptors.
It is important to note that our results do not exclude the possibility that v-Abl may also activate STATs directly. V-Abl may recruit and phosphorylate STATs using other signaling proteins. It is, therefore, possible that JAK 1 may provide a large portion, but not all, of the STAT activation signal by v-Abl. Furthermore, our biochemical analysis does not exclude the importance of other domains of v-Abl in JAK 1 regulation. In other words, JAK 1 binding to vAbl is required, but may not be sucient for v-Ablinduced JAK 1 activation. Indeed we have recently examined additional mutation in the carboxyl terminus portion of v-Abl, and found that the sequences 3' to the JAK 1-binding domain may play an important role in JAK 1 activation, but not JAK 1 binding downstream of v-Abl (NN Danial and PB Rothman, unpublished observations). Thus, we propose that at least three requirements must be satis®ed for JAK 1 activation by v-Abl: (1) an active v-Abl kinase, (2) an intact JAK 1 binding domain in the carboxyl terminus of v-Abl and (3) an intact`JAK 1 regulatory domain' further downstream of the JAK 1 binding domain. The nature of signaling pathways regulated by this JAK 1 regulatory domain, and whether similar signaling pathway functions normally in cytokine-stimulated JAK 1 activation await further analysis.
In addition to activation of positive eectors in cytokine signal transduction, the mechanism of v-Ablinduced JAK-STAT activation may involve suppression of inhibitory signals that normally operate to terminate cytokine signaling. This is especially noteworthy in light of the fact that unlike cytokine-induced JAK-STAT signaling, v-Abl-induced JAK-STAT activation is not transient. Data from our laboratory have further suggested that IL-7 can only transiently substitute for multiple functions of v-Abl, when ts AMuLV pre-B cells are shifted to non-permissive temperatures (Banerjee and Rothman, 1998) . In AMuLV-transformed cells, the protein levels or the state of phosphorylation/activation of proteins implicated in negative regulation of JAKs and STATs, including SOCS or PIAS family of molecules (Hilton, 1999; Shuai, 1999) , have not been examined. Recent reports have suggested that SOCS proteins may be highly regulated at the level of gene transcription and protein degradation (Kamura et al., 1998; Narazaki et al., 1998) . It is possible that the transformation program by v-Abl may involve selective degradation/repression of these proteins, in addition to the activation of JAKs and STATs.
Constitutive activation of JAKs and STATs by vAbl may, in turn, re¯ect inactivation of speci®c JAK or STAT phosphatase activity. Several protein tyrosine phosphatases have been implicated in modulating signals initiated by cytokines. Shp-1 (HCP/PTP1C) can interact with several cytokine receptors, and may be important in terminating STAT activation Neel and Tonks, 1997) . On the other hand, a dominant negative mutant of Shp-2 (SYP/PTP1D) was shown to inhibit STAT 5 activation downstream of the prolactin receptor by inactivating JAK 2, suggesting that this SH2 containing tyrosine phosphatase is a positive regulator of JAK-STAT signaling (Berchtold et al., 1998) . Shp-2 has also been identi®ed as a JAK 1 and JAK 2 binding protein and substrate (Marrero et al., 1998; Yin et al., 1997) . Transformation signal by v-Abl may down-regulate Shp-1-like signals and up-regulate Shp-2-like signals. The functional importance of the above-mentioned tyrosine phosphatases in v-Abl-induced JAKs and STAT activation is not known.
Activation of the JAK-STAT pathway by BCR-Abl
Constitutive activation of STATs in extracts derived from BCR-Abl-expressing cell lines or samples derived from patients with Philadelphia chromosome-positive CML and ALL has also been examined. While one report did not ®nd constitutive STAT activation in BCR-Abl-expressing samples from ALL patients (Kanwar et al., 1996) , several other studies have reported constitutive STAT activation in both cell lines and patient samples expressing this oncoprotein (Carlesso et al., 1996; Chai et al., 1997; GouilleuxGruart et al., 1996; Ilaria and Van Etten, 1996; Shuai et al., 1996; Wilson-Rawls et al., 1996) . Studies from our laboratory have shown that STAT 5 is the major STAT activated in both cell lines and patient samples expressing BCR-Abl (Chai et al., 1997) . However, in samples from some CML patients the GAS binding activity corresponded to STAT 1 and not STAT 5. In one case the GAS binding activity could not be identi®ed by any antiserum available to human STATs.
The p190, p210, and p230 forms of BCR-Abl have been found in dierent subsets of Ph-positive leukemias. Recent experiments have also shown that p190 can generate lymphoid leukemia with shorter latency than p210 (Li et al., 1999) . It is interesting that p210 and p190 dier in their ability to activate STAT 6 (Ilaria and Van Etten, 1996) . While both forms of BCR-Abl can activate STAT 5, STAT 6 activation has only been reported downstream of p190. The ability to activate STAT 6 is the ®rst biochemical dierence described for these two forms of BCR-Abl. Taken together, the above observations suggest that in both cell lines and patient samples, constitutive GAS binding activities corresponding to various STATs can be correlated with the presence of BCR-Abl. The relationship between the particular STAT activated and the pathology of the disease, or the molecular mechanism underlying this dierential STAT activation is not clear.
The mechanism by which BCR-Abl activates STATs may be dierent than v-Abl. Although the human oncogenic form of Abl, BCR-Abl, and the murine oncogenic form v-Abl share many common characteristics, several structural and functional dierences between the two have been reported. It appears that the activation of JAK-STAT signaling by these two forms of Abl may be another example of biologic dierences between these oncoproteins. Unlike v-Abl, association of BCR-Abl and JAKs has not been detected 1997 (Ilaria and Van Etten, 1996) . The lack of BCR-Abl : JAK association may re¯ect structural dierences between these two proteins. It is possible that sequences within the BCR region or the Abl SH3 domain which are present in BCR-Abl, but not v-Abl (Figure 1 ), contribute to protein folding or proteinprotein interactions rendering C-terminal sequences inaccessible for JAK 1 binding. Alternatively, the Cterminus of BCR-Abl may not be able to bind JAK kinases. Comparison of Abl protein sequences reveals that although there is a high degree of homology (99%) between murine and human c-Abl in the SH2 and kinase domains (Fainstein et al., 1989) , the C-terminus regions (corresponding to the JAK 1-binding domain of v-Abl) are 68% identical. Therefore, it is possible that critical amino acids required for JAK 1 binding within this region are not present in the human protein.
Although JAK kinases have not been consistently detected in BCR-Abl immunoprecipitates, several independent studies have shown constitutive activation of JAK 1 (Chai et al., 1997; Ilaria and Van Etten, 1996; Shuai et al., 1996) and variable activation of Jak 2 in BCR-Abl-expressing cells (Chai et al., 1997; Henderson et al., 1997 ). An independent study demonstrated that kinase inactive mutants of JAK 2 do not block constitutive activation of STAT 5 in BCR-Abl expressing BAF/3 cells (Ilaria and Van Etten, 1996) . The eect of a kinase inactive mutant of JAK 1 was not tested. Thus, it is still not clear whether activation of STATs by BCR-Abl is JAK independent. It is possible that BCR-Abl directly activates STATs, or that it targets its kinase activity to STATs through a dierent interacting protein(s).
A recent report has suggested that the mechanism of BCR-Abl-induced STAT activation may be similar to Src (Chaturvedi et al., 1997) . Like Src-induced STAT activation, the SH2 and SH3 domains of BCR-Abl are required for constitutive activation of STAT 5 by this oncoprotein (Chaturvedi et al., 1997; NieborowskaSkorska et al., 1999) . These same studies did not explore the eect of mutations in the carboxyl terminal portion of BCR-Abl on STAT activation. How the SH2 and SH3 domains signal STAT activation has not been studied in detail. Unlike Src, BCR-Abl does not associate with any STAT. As the FLVRES mutation in BCR-Abl does not aect the ability of BCR-Abl to activate STAT 5, it appears that the SH2-phosphotyrosine interaction between BCR-Abl and STAT5 is not required for constitutive STAT activation by this oncoprotein. It has been proposed that the SH2 and SH3 domains together may form the binding pocket for a protein substrate that may ultimately be important in STAT 5 activation by BCR-Abl. A possible candidate for such a protein substrate could be the adapter protein CrkL. It has been shown that CrkL and STAT 5 associate in vivo (Ota et al., 1998; Ozaki et al., 1998) . Because CrkL can be recruited to BCR-Abl directly by binding to the Cterminal proline rich sequences in BCR-Abl (Oda et al., 1994) , or indirectly via proteins that bind the SH3-SH2 domains of BCR-Abl, it is possible that CrkL may recruit STAT 5 to BCR-Abl. Another possibility may be that BCR-Abl mediates STAT phosphorylation through another kinase. Interestingly, two Src family kinases, p53/56 Lyn and p59 Hck, are activated in BCR-Abltransformed cells, and associate with this protein in vivo (Warmuth et al., 1997) . These possible modes of BCRAbl-induced STAT 5 activation have not been tested.
Biological significance of JAK activation by v-Abl
As noted earlier in this review, growth factor independent proliferation, resistance to apoptosis, and transformation are the properties of cells infected with A-MuLV. Because v-Abl can activate multiple signaling pathways (Figure 2) , the mechanism by which it transforms cells is likely to be extremely complex. Blocking activation of various signaling proteins has been shown to block, or partially interfere, with transformation by Abl oncoproteins. These include Myc (Sawyers et al., 1992) , Ras (Pendergast et al., 1993; Sawyers et al., 1995) , Jun (Raitano et al., 1995) and Akt . The transformation program may re¯ect the collective eects of dierent signals; those inducing dysregulated growth, those allowing cells to escape from apoptotic crisis often associated with v-Abl transformation prior to full immortalization of A-MuLV-infected cells, and those determining the latency of tumor formation. Signaling molecules that cooperate with v-Abl in transformation may function at one or more of these levels.
A role for JAKs and STATs in proliferation, protection from apoptosis, and oncogenesis has been suggested. Constitutively active JAKs may be tumorigenic, at least in two settings. First, gain of function mutations in the Drosophila homolog of JAK, hopscotch, can cause tumors in¯ies, indicating that hyperactive JAKs may be oncogenes (Hanratty and Dearolf, 1993; Harrison et al., 1995) . Second, a constitutively active form of JAK2, in form of the TEL/JAK 2 fusion product, has been identi®ed in chromosomal translocations found in atypical CML and pre-B cell ALL (Peeters et al., 1997) .
Whether constitutive JAKs and STATs are sucient for malignant transformation has been the subject of many recent reports. A gain of function mutation in murine JAK 2, which was engineered to mimic that in the Drosophila tumorigenic allele of hopscotch, can activate STAT 5, but cannot bypass the requirement for cytokines in proliferation of factor dependent cells (Luo et al., 1997) . On the other hand, the TEL/JAK 2 fusion protein can transform factor dependent cell lines or primary bone marrow cells, and can generate tumors in mice (Ho et al., 1999; Schwaller et al., 1998) . This oncogenic JAK 2 fusion protein can activate STATs 1, 3 and 5 eciently (Ho et al., 1999) . It is, however, not clear whether activation of STATs is part of the oncogenic program downstream of TEL/JAK 2. An independent study reported that although a dominant negative interfering mutant of STAT 5 can reduce the eciency of BCR-Abl transformation by 60 ± 75%, a constitutively active form of STAT 5 alone is not sucient to transform primary murine bone marrow cells (NieborowskaSkorska et al., 1999) . In these experimental systems, it appears that STATs in themselves may not be oncogenic. Interestingly, this form of STAT 5 could rescue some but not all the transformation defective mutants of BCR-Abl (Nieborowska-Skorska et al., 1999) . This implies that STAT 5 activation may be important in tumorigenicity, but not sucient for this process, and that phosphorylation/activation of other substrates by BCR-Abl may be required for oncogenesis. Collectively, the above observations suggest that JAKs and STATs can provide part of the signaling required for cellular transformation.
We have assessed the importance of JAK 1 in two aspects of v-Abl biology; cytokine independent proliferation and cellular transformation. The latter has been examined both at the level of tumor growth in animals and contact independent growth in soft agar PKC and cdc2 indicate phosphorylation consensus site for these serine kinases assays. We ®nd that the JAK 1-binding domain of vAbl is required for v-Abl-induced, cytokine independent growth and survival. BAF/3 cells expressing wildtype v-Abl show 20 ± 30-fold higher proliferation than those expressing a mutant of v-Abl de®cient in JAK 1 binding. Furthermore, in BAF/3 cells stably expressing wild-type v-Abl and a peptide spanning the JAK 1-binding domain of this oncoprotein, IL-3-independent proliferation is severely reduced (NN Danial and PB Rothman, unpublished observations) . This is consistent with our observation that, inducible expression of a kinase inactive mutant of JAK 1 inhibits the ability of v-Abl to support cytokine independent proliferation (Danial et al., 1998) .
In addition, cells expressing the JAK 1-binding mutant of v-Abl show decreased frequency and extended latency in generating tumors in nude mice. While 94% of the nude mice injected with BAF/3 cells expressing wild-type v-Abl developed tumors within 10 days, only 10% of the mice injected with cells expressing the JAK 1-binding mutant of v-Abl exhibited signs of tumor growth (Danial et al., 1998) . We have further assessed the importance of JAK 1 binding and activation by v-Abl in transformation of primary cells, namely bone marrow. Bone marrow cells transduced with JAK 1-binding mutants of v-Abl exhibit reduced eciency (72 ± 75% reduction) in forming colonies in soft agar (NN Danial and PB Rothman, unpublished observations). Moreover, we have generated bi-cistronic viruses to co-express a kinase inactive mutant of JAK 1 and wild-type v-Abl, and have found a reduction in the eciency of v-Abl to transform bone marrow cells by approximately 65% (NN Danial and PB Rothman, unpublished observations). These results suggest that the Jak 1-binding domain of v-Abl and JAK 1 kinase activity may play an important role in transformation by this oncogene.
In addition to STATs, JAK kinases have recently been shown to activate other signaling pathways. Identi®cation of JAK-interacting proteins, in combination with studies using Jak-binding mutants of cytokine receptors have implicated a role for JAKs in mitogenesis and cell survival. In order to address the molecular mechanism underlying the proliferation and transformation defect of the JAK 1-binding mutant of v-Abl, we have recently analysed multiple signaling pathways downstream of this mutant compared to the wild-type v-Abl protein. We have found a selective defect in the JAK 1-binding mutant of v-Abl in activating the Ras and PI3-kinase signaling pathways. These observations are further supported by the fact that inducible expression of a kinase inactive JAK 1 downstream of wild-type v-Abl reduces the ability of v-Abl to activate Ras and PI3-kinase (Danial et al., 1998 and NN Danial and PB Rothman, unpublished observations) . Together, our results suggested that a functional link may exist between the Ras/PI3-kinase pathways and JAK 1 downstream of the carboxyl terminus of v-Abl (Figure 2) .
It is important to note that our observations do not exclude the possibility that other domains of v-Abl, in addition to the JAK 1-binding region, are involved in activating these same pathways. In fact, v-Abl, like other oncoproteins has evolved multiple alternative ways of activating the same signaling pathway. This, in turn, may re¯ect the importance of providing certain threshold of signaling necessary for oncogenesis. It is also possible that deleting the JAK 1-binding domain of v-Abl may aect binding of other factors besides JAK 1, which may result in the reduced activation of the above-mentioned signaling pathways. Our experiments with inducible expression of a kinase inactive JAK 1 suggest that JAK 1 function may be important in activation of STATs, Ras and PI3-kinase. An important functional test for the observations we have described above would be to examine the role of these pathways, individually or in combination, in restoring the proliferation and transformation defects of JAK 1-binding mutants of v-Abl.
The importance of the Abl carboxyl terminus portion in activation of JAKs, STATs, Ras and PI3-kinase is intriguing in light of previous studies, which proposed a role for this region in v-Abl function. Naturally occurring mutant strains of A-MuLV that encode v-Abl proteins with truncations in the carboxyl terminus region exhibit severe defects in transformation of bone marrow cells but not ®broblasts in vitro (Prywes et al., 1983; Rosenberg et al., 1980) (Figure 1 ). In vivo, however, these A-MuLV mutant strains give rise to some tumors (Murtach et al., 1986) . It has therefore been proposed that the carboxyl terminus portion of v-Abl plays an important role in regulating the transforming activity of this protein. Furthermore, experiments in which various regions of src and abl oncogenes were used to generate hybrid retroviral genomes have shown that the C-terminal domain of vAbl, in addition to the 3' end of Abl kinase domain, are sucient to confer pre-B cell transforming property to src retroviruses (Hevezi et al., 1993) . This is especially interesting, as Src, unlike v-Abl, does not generate pre-B cell tumors in vivo.
Several models may be suggested to explain the dierential requirement of v-Abl C-terminus in transformation of ®broblasts versus pre-B cells. First, this region of v-Abl may activate cell type speci®c signaling pathways that may be required for transformation. Within the carboxyl terminus of Abl, several functional domains have been identi®ed. These include multiple proline-rich regions that bind SH3 containing molecules (Feller et al., 1994) , a region (in c-Abl) that binds p53 (Goga et al., 1995) , a region shown to be important for c-Abl to bind DNA (Kipreos and Wang, 1992) , a region that binds the amphiphysin-like protein1 (ALP1) (Kadlec and Pendergast, 1997) , and an F/G actin binding domain (McWhirther and Wang, 1991; Van Etten et al., 1989b) . However, characterization of molecular interactions involving the C-terminus of v-Abl has not identi®ed a cell type speci®c signaling pathway that may potentially explain the requirement of this domain in pre-B cell transformation or in pre-B cell selectivity of A-MuLV in vivo. The JAK-STAT pathway is also activated in both pre-B and ®broblasts transformed by A-MuLV. Second, the carboxyl terminal region may regulate signaling pathways that are redundant in some cell types and not others. In other words, whether the C-terminus of v-Abl is required for transformation of one set of targets versus another may ultimately depend on whether there exist compensatory pathways in one cellular target (®bro-blasts) and not the other (pre-B cells) that can substitute for those activated by the C-terminus of vAbl. According to this model for example, one can propose that in ®broblasts, the combined eects of signaling pathways activated by the SH2 and the kinase domains of v-Abl is sucient to complete the transformation program. In pre-B cells, activation of STATs, Ras and PI3 kinase pathways by the carboxyl terminal region of v-Abl may be additionally required for transformation.
The JAK-STAT pathway and c-Abl
The amino acid region spanning the JAK 1-binding domain of v-Abl is conserved in c-Abl, suggesting that c-Abl may have JAK 1-binding property. Our initial co-immunoprecipitation experiments with endogenous levels of JAK 1 and c-Abl suggested that there may be very low level association between these two kinases (NN Danial and PB Rothman, unpublished observations). In transient co-transfection experiments with STAT reporter constructs, a small increase in STAT activation can be detected when c-Abl is co-transfected, suggesting that c-Abl may be able to activate STATs. Whether there exist a functional link between c-Abl and the JAK-STAT pathway in vivo is not clear. Examination of this possible link may be complicated because the in vivo kinase activity of c-Abl is tightly regulated, and the cytoplasmic pool of c-Abl that could be available for JAK 1 binding may be limited.
Initially, it appeared that the carboxyl terminal potion of c-Abl may be required for IL-7 responsiveness, as progenitor B cells from some c-Abl m1/m1 mice (in which the carboxyl terminus of c-Abl was replaced by a neo cassette) did not proliferate in response to IL-7 (Hardin et al., 1995) . Subsequent studies, however, showed that Whitlock-Witte long term bone marrow cultures could be established from these mice, and that these cell lines could activate JAK 1 and JAK 3 in response to IL-7 (Dorsch and Go, 1996) . Mice with targeted disruption of the cAbl kinase domain have not been analysed for IL-7 responsiveness. The above observations can be interpreted in several ways. The SH2 and the kinase domains of c-Abl may be sucient for IL-7 responsiveness and JAK activation in c-Abl m1/m1 mice. Alternatively, c-Abl protein may not be required for IL-7 responsiveness. The carboxyl terminus of c-Abl is, however, important in protecting progenitor B cells from apoptosis induced by various stimuli, and may explain the severe reduction in the size of progenitor B cell compartment in these mice (Dorsch and Go, 1996) .
The phenotype of the c-Abl de®cient mice has suggested that both the kinase domain and the carboxyl terminal region of c-Abl are required for early B cell development (Schwartzberg et al., 1991; Tybulewicz et al., 1991) . It is also noteworthy that the IL-7/IL-7R, JAK 1, or JAK 3 de®cient mice have a similar phenotype in early B cell development. It is possible that downstream of IL-7R and JAK kinases, c-Abl may be required for cell cycle progression or survival of pre-B cells, and not their dierentiation per se. Examination of subcellular localization and changes in the c-Abl kinase activity following cytokine (IL-7) treatment will be important to establish the connection between c-Abl and cytokine signal transduction.
Discussion
Previous work has established that the carboxyl terminus of v-Abl plays a complex role in regulating the function of this protein in vivo. The JAK 1 binding domain within this region is required for ecient transformation by v-Abl. The studies described here have shed light on additional pathways that are regulated by this portion of v-Abl. Biochemical characterization of these pathways suggest that JAK 1 may play an important role in v-Abl-mediated activation of STATs, Ras, and PI-3 kinase. Our observations are consistent with studies using other experimental systems to show that JAK kinases may be involved in regulation of multiple signaling pathways. Examining speci®c contribution of JAK kinases to oncogenic processes may be insightful, at the biochemical and functional level, with regard to the biology of JAKs. Lessons learned from such studies may further be applied to unravel novel functions of JAKs in cytokine signaling under normal settings. Our observations may also be relevant in understanding the function of c-Abl and BCR-Abl.
